 Brian Jamieson FCA
Non-Executive Chairman
Brian Jamieson was Chief Executive of Minter Ellison Melbourne and a partner of the Minter Ellison Revenue Group from 2002-2005. He retired as Chief Executive of Minter Ellison Melbourne on 31 December 2005. Prior to joining Minter Ellison, Mr Jamieson was Executive Officer at KPMG from 1998-2000, Managing Partner of KPMG Melbourne and Southern Regions from 1993-1998 and Chairman of KPMG Melbourne from 2001-2002. He was also a KPMG Board Member in Australia , and a member of the USA Management Committee.
|  Donal O'Dwyer, BE, MBA
Non-Executive Deputy Chairman
Mr O'Dwyer has almost 20 years experience as a senior executive in the global cardiovascular and medical devices industries. From 2000 to 2003, he was worldwide president of Cordis Cardiology, the cardiology division of Johnson & Johnson's Cordis Corporation. Cordis is the world's largest manufacturer of innovative products for interventional medicine, minimally invasive computer-based imaging, and electrophysiology. In this role, Mr O'Dwyer led Cordis through the launch of the revolutionary Cypher drug eluting coronary stent technology, and saw the company take over number one market share of coronary stents worldwide.
|  Professor Silviu Itescu, MBBS (Hons), FRACP, FACP, FACR
Director and Chief Scientific Adviser
Professor Itescu is the Founder of Mesoblast Limited and Angioblast Systems, Inc. Most recently Director of Transplantation Immunology at New York 's Columbia University Medical Center , Professor Itescu has established an outstanding international reputation in the fields of stem cell biology, autoimmune diseases, organ transplantation and heart failure. His experiences range from laboratory research to new drug development and clinical evaluation. Professor Itescu pioneered novel approaches to the use of adult stem cells for the treatment of heart disease and is leading international collaborative trials in this area.
|  Michael Spooner, BCom, ACA, MAICD
Non-Executive Director
Mr Spooner has an extensive network of relationships with investment firms and business communities across the globe, having spent the majority of the past 25 years living and working internationally. He has an outstanding track record in the rapid international commercialisation of high growth companies including within the medical application and commercial technology sectors. Most recently, Mr Spooner was Managing Director & CEO of Ventracor Limited where he led the transformation of a small Australian listed life sciences company into the second highest performing stock on the S&P/ASX 200 index in 2003.
|  Byron McAllister, B.Sc, M.Ag
Non-Executive Director
Mr McAllister has extensive expertise in product development, quality assurance, and obtaining FDA regulatory approvals within the healthcare industry. He has extensive expertise within the biologics, pharmaceutical, and medical device industries, and has prepared full documentation for approval by the U.S. FDA, UK MCA, and other world health regulatory authorities. Most recently, Mr McAllister has served as Vice President, Worldwide Quality Assurance, for the Ares-Serono Group based in Geneva and Boston , overseeing operations in over a dozen countries. Mr McAllister has held senior management positions in manufacturing and quality assurance with Abbott Laboratories' Ross Laboratories and Diagnostics Divisions, Amersham Corporation, and Coulter Electronics Corporation.
|  Kevin Hollingsworth, FCPA, FCMA
Company Secretary
Mr. Hollingsworth is a certified public accountant, and a past chairman of both the National and Victorian Industry and Commerce Accountants Committees. Mr. Hollingsworth has most recently been non-executive director and company secretary for Alpha Technologies Corporation Ltd, a global company with operations in the US, Mexico and China, designing and manufacturing temperature sensors for disposable medical devices, as well as precision thermometry and instrumentation for the biotechnical and life science industry.
|
|
MSB.AX
ASX S&P200
ASX:MSB
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.
